Hôpital La Colombière
- Address
- 39 Avenue Charles Flahaut, 34090 Montpellier, France
Hôpital La Colombière - HIV Treatment Research Center
Hôpital La Colombière is a specialized research facility focused on advancing HIV-1 treatment strategies through comprehensive clinical trials. The center demonstrates particular expertise in evaluating novel antiretroviral therapies and comparative effectiveness studies in both treatment-naïve and treatment-experienced populations living with HIV.
- Phase III trials comparing next-generation antiretroviral regimens including doravirine and dolutegravir-based combinations
- Long-term safety and efficacy evaluations of innovative HIV treatment combinations in treatment-experienced patients
- Virologic efficacy assessment and non-inferiority studies in antiretroviral therapy
The center's research portfolio emphasizes both the establishment of new treatment standards through comparative non-inferiority trials and the longitudinal monitoring of emerging therapeutic options. With involvement in multicenter international studies, Hôpital La Colombière contributes valuable data on treatment optimization and expanded therapeutic choices for people living with HIV-1 infection.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hôpital La Colombière
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Open-label Clinical Study of Doravirine/Islatravir (DOR/ISL [100 mg/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL (100 mg/0.75 mg) QD in a Phase 3 Clinical Study | Merck Sharp & Dohme LLC | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Doravirine | 2 | Unknown | 2025-01-08 | 2025-01-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.